Denali Therapeutics Inc. (DNLI)

15.43 +0.47 (+3.14%) At close: 04:00PM EDT

Denali Therapeutics Inc.

161 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 866 8548
https://www.denalitherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 445

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ryan J. Watts Ph.D.	Co-Founder, President, CEO & Director	1.15M	3.65M	1976
Dr. Alexander O. Schuth M.D.	Co-Founder, CFO, COO & Secretary	802.29k	1.65M	1973
Dr. Marc Tessier-Lavigne Ph.D.	Co-Founder & Independent Director	57.5k	N/A	1960
Dr. Carole Ho M.D.	Chief Medical Officer & Head of Development	802.29k	N/A	1973
Mr. Tyler M. Nielsen	Senior Vice President of Corporate Finance	N/A	N/A	1978
Dr. Dana Andersen	Chief Technical and Manufacturing Officer	N/A	N/A	N/A
Mr. Joe Lewcock Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Dr. Laura Hansen	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Chris Walsh	General Counsel	N/A	N/A	N/A
Mr. Mark Rowen	Vice President of Corporate Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Corporate governance

Denali Therapeutics Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.